Persbericht Biocartis Group NV: Biocartis kondigt H1 2021 resultaten aan

NEXT STORY
Precision BioSciences and Tiziana Life Sciences Announce Exclusive License Agreement to Evaluate Foralumab, a Novel, Fully Human Anti-CD3 Monoclonal Antibody, in Conjunction with Allogeneic CAR T Candidates for Cancer Treatment
PREV STORY
Press news Biocartis Group NV: Biocartis Launches Idylla™ SARS-CoV-2/Flu/RSV Panel
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Helsinn and CJ Healthcare announce the approval of AKYNZEO® oral formulation in Korea

Helsinn and CJ Healthcare announce the approval of AKYNZEO® oral formulation in Korea CINV ...

author_avatar
NASDAQ Market News

Kleo Pharmaceuticals Presents Preclinical Data on KPMW135, a Novel CD3 x CD20 Bispecific Version of Rituximab, Showing Increased Anti-Tumor Activity Compared to Rituximab, at The 62nd Annual American Society of Hematology (ASH) Meeting

author_avatar
NASDAQ Market News

Biodesix Announces New Data Demonstrating Analytic Validity of Automated RNA Extraction from Plasma with the GeneStrat® Test

BOULDER, Colo., Nov. 16, 2017 (GLOBE NEWSWIRE) -- Biodesix® announced data demonstrating that a ...

author_avatar
NASDAQ Market News